CA-CEPTON-TECHNOLOGIES
9.9.2019 15:02:04 CEST | Business Wire | Press release
CNL Software, a world leader in Physical Security Information Management (PSIM) software, is pleased to announce a technology partnership with Cepton Technologies, a developer of industry-leading 3D sensing solutions, at the GSX in Chicago. The partnership will drive the automation of threat detection, tracking and escalation in real time using the latest PSIM, LiDAR and video assessment technologies.
Cepton Technologies’ Helius™ system is a smart lidar network utilizing edge computing to provide real-time detection, tracking and classification. It can seamlessly track an object from sensor to sensor, providing 3D data on location, dimensions, and velocity, while maintaining the same identification of the object.
By connecting multiple laser-powered sensors, it offers comprehensive coverage of a given area as well as high resolution imaging of objects. Sensors can be clustered as needed but act as one to maximize the simplicity of use and integration. With the in-built software in the hardware unit, Helius is browser-based and can launch on computers and mobile devices for instant monitoring and configuration, without installations of additional software. Furthermore, being edge-based, Helius processes data locally and outputs low-bandwidth data to the central server.
“CNL Software is committed to working with new and innovative technologies that will give our customers improved security and greater efficiency. Cepton’s lidar sensor technology brings the technological leaps that have taken place in autonomous vehicles to the security industry, especially in the government and critical infrastructure markets where we are experiencing growing demand for the integration of multiple different security system and sensor technologies,” comments Keith Bloodworth, CEO, CNL Software. “When integrated with IPSecurityCenterTM , Helius further enhances the industry’s most comprehensive PSIM system solution, providing users with access to more of the tools they need to quickly see, understand, assess and properly resolve perimeter security and surveillance incidents, consistently.”
Neil Huntingdon, Cepton’s VP of Business Development, added: “Our technology’s ability to detect and track events in traditionally difficult environments combined with IPSecurityCenter’s ability to correlate this data with data from other security systems and sensors and provide decision support is a powerful proposition. We’re really excited to be partnering with CNL Software to bring this game changing solution to the government, critical infrastructure, safe city and transportation markets, in particular. It will unlock that ‘missing layer’ by filling the medium-range sensor gap and improve it with the capability to classify objects as well as behaviors.”
For more information about CNL Software’s PSIM solution and deployments, please visit Booth #1713 at the GSX in Chicago on September 10– 12 2019. To book a demonstration, please email marketing@cnlsoftware.com
About Cepton Technologies, Inc.
Cepton Technologies, Inc. is a 3D sensing solutions provider shipping state-of-the-art lidar products for the automotive, security, transport infrastructure, industrial, IoT and mapping markets.
Founded in 2016 and led by industry veterans with deep experience in lidar and advanced imaging, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions for the automotive industry and beyond.
Cepton’s patented lidar technology delivers outstanding detection range and resolution, reliability and affordability, to enable perception for the fast-growing market for autonomous and smart machines. For more information, visit: http://www.cepton.com/ .
Cepton will also have a separate booth at stand 1894, next to the bistro.
About CNL Software
More than a decade ago, we set out to create a PSIM platform to transform the way organizations manage their physical security. Today, IPSecurityCenter is trusted by the best-informed security operations in national security, critical infrastructure and large enterprises around the world. For more information, visit www.cnlsoftware.com .
Physical Security Information Management (PSIM) LinkedIn Group
The PSIM Group brings together users, integrators, consultants and manufacturers of Physical Security Information Management software to share ideas, thought leadership, tips, tricks, future developments and more! Please follow visit https://www.linkedin.com/groups/2162880
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909005033/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
